ES2088464T3 - Uso y administracion de enzimas. - Google Patents

Uso y administracion de enzimas.

Info

Publication number
ES2088464T3
ES2088464T3 ES91302397T ES91302397T ES2088464T3 ES 2088464 T3 ES2088464 T3 ES 2088464T3 ES 91302397 T ES91302397 T ES 91302397T ES 91302397 T ES91302397 T ES 91302397T ES 2088464 T3 ES2088464 T3 ES 2088464T3
Authority
ES
Spain
Prior art keywords
enzymes
target
administration
enzyme
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91302397T
Other languages
English (en)
Inventor
Thomas Stewart Beggs
Paul James Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909006328A external-priority patent/GB9006328D0/en
Priority claimed from GB909021671A external-priority patent/GB9021671D0/en
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2088464T3 publication Critical patent/ES2088464T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/94—Involves covalent bonding to the substrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UNO O MAS VEHICULOS, QUE PUEDEN SER ACEPTABLES DE ENTRAR EN LA BOCA, CONTIENEN AL MENOS UNO O DOS ENZIMAS COOPERANTES MAS UN ANTICUERPO O FRAGMENTO DE ANTICUERPO QUE SE UNE A UN BLANCO. HAY MEDIOS PARA ATACAR AMBAS ENZIMAS A DICHOS ANTICUERPOS O SUS FRAGMENTOS, PARA ASI UNIR LAS ENZIMAS A LA VECINIDAD DEL BLANCO. UNA ENZIMA GENERA UN INTERMEDIARIO, EL CUAL ES UTILIZADO POR LA OTRA ENZIMA PARA GENERAR UNA SUBSTANCIA, PREFERIBLEMENTE HIPOALITA, QUE ACTUA EN DONDE ESTA EL BLANCO.
ES91302397T 1990-03-21 1991-03-20 Uso y administracion de enzimas. Expired - Lifetime ES2088464T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909006328A GB9006328D0 (en) 1990-03-21 1990-03-21 Cell killing
GB909021671A GB9021671D0 (en) 1990-10-05 1990-10-05 Delivery of agents

Publications (1)

Publication Number Publication Date
ES2088464T3 true ES2088464T3 (es) 1996-08-16

Family

ID=26296815

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91302397T Expired - Lifetime ES2088464T3 (es) 1990-03-21 1991-03-20 Uso y administracion de enzimas.

Country Status (9)

Country Link
EP (1) EP0450800B1 (es)
JP (1) JPH04234821A (es)
AT (1) ATE139704T1 (es)
AU (1) AU642979B2 (es)
BR (1) BR9101118A (es)
CA (1) CA2038577C (es)
DE (1) DE69120452T2 (es)
ES (1) ES2088464T3 (es)
IN (1) IN172886B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
AU642980B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US5486360A (en) * 1993-04-22 1996-01-23 St. Joseph Health Centre Method of treating tumour cells using catalase
EP0868199A1 (en) * 1995-12-21 1998-10-07 Quest International B.V. Particle compositions
US5972355A (en) * 1997-09-30 1999-10-26 E-L Management Corp. Stable compositions containing biologically active components
US5871714A (en) * 1997-10-16 1999-02-16 Pharmacal Biotechnologies, Inc. Compositions for controlling bacterial colonization
EP1787627A1 (en) 2005-11-17 2007-05-23 3M Innovative Properties Company Anti-microbial dental impression material
EP2655646A4 (en) 2010-12-20 2014-05-21 Du Pont TARGETED PERHYDROLASES
RU2660373C2 (ru) 2010-12-20 2018-07-05 Е.И.Дюпон Де Немур Энд Компани Ферментативное образование перкислоты для применения в продуктах для ухода за полостью рта

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433593A (en) * 1972-06-09 1976-04-28 Royal College Of Surgeons Conjugates
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
EP0271180B2 (en) * 1986-08-18 1997-06-18 The Dow Chemical Company Starburst conjugates
US4943525A (en) * 1987-11-02 1990-07-24 Bioventures, Inc. Simultaneous immunoassay for the determination of antigens and antibodies
SE461570B (sv) * 1988-06-06 1990-03-05 Rama Bio Link Ab Farmaceutiskt preparat och konjugat av en baktericid och en antikropp
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics

Also Published As

Publication number Publication date
JPH04234821A (ja) 1992-08-24
EP0450800A1 (en) 1991-10-09
DE69120452T2 (de) 1996-10-31
DE69120452D1 (de) 1996-08-01
CA2038577C (en) 2001-06-19
IN172886B (es) 1993-12-25
AU7299691A (en) 1991-10-03
CA2038577A1 (en) 1991-09-22
EP0450800B1 (en) 1996-06-26
BR9101118A (pt) 1991-11-05
AU642979B2 (en) 1993-11-04
ATE139704T1 (de) 1996-07-15

Similar Documents

Publication Publication Date Title
FI962350A0 (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
MX9203439A (es) Una citocina mamifera, il-11
EA199800946A1 (ru) Концентрированный препарат антител
MX9800422A (es) Procedimiento para estabilizar proteinas en una ambiente acido, con una pectina de elevado contenido de ester.
BG101103A (bg) Теломераза при бозайници
ES2088464T3 (es) Uso y administracion de enzimas.
NO179615C (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
ES2056817T5 (es) Transformacion de trichoderma.
ES2055375T3 (es) Procedimiento y dispositivo para el reconocimiento de un blanco.
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
UA27035C2 (uk) Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
DK0819135T3 (da) Kulhydratmodificerede cytostatika
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
ES2088463T3 (es) Uso de enzimas.
CO4930284A1 (es) Formulaciones novedosas solidas de calcitonina
FR2677653B1 (es)
ES2117067T3 (es) Procedimiento para la determinacion inmunoquimica de un analito.
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 450800

Country of ref document: ES